Most people don’t hear about TMS therapy until they’re already a few steps into psychiatric treatment. That’s how the system is designed: Certain tools come up only after earlier ones have been tried. TMS is one of those tools, and knowing where it typically enters the picture can make the whole process feel a lot less confusing.
This article covers when TMS tends to be considered, how it’s used alongside other depression treatment options, and how clinicians work it into a care plan that keeps evolving.
Quick Answer Summary
TMS therapy is typically introduced after standard depression treatments, such as antidepressants and psychotherapy, have not provided sufficient relief. It is considered part of advanced psychiatric care and is often used alongside ongoing therapy, medication management, and lifestyle interventions. Research shows that TMS is most effective when integrated into a structured treatment plan, where clinicians continuously monitor progress, adjust care, and incorporate maintenance strategies when needed.
The Structure of Psychiatric Treatment for Depression
Depression care tends to follow a recognizable hierarchy. Most clinicians start with first-line options: antidepressant medications and psychotherapy, sometimes used together. If those produce partial results or aren’t tolerated well, augmentation strategies, such as adding a second medication, switching classes, or layering in more intensive therapy, come next. Advanced interventional options enter the picture further along in that process.
This structure exists for a reason. Less invasive options come first partly to spare patients from side effects they didn’t need to take on, and partly because those early trials build a record. By the time a clinician brings up TMS, they usually have a real picture of what’s moved the needle and what hasn’t. That history shapes the conversation. It’s not a random suggestion. Rather, it follows from what’s already happened in care.
Where TMS Therapy Sits in the Sequence
TMS therapy is generally considered after one or more standard medication trials haven’t produced enough improvement. The VA/DoD Clinical Practice Guideline for Major Depressive Disorder places TMS in the advanced care management portion of depression treatment, recommending clinicians consider it for patients with partial or no response to two or more adequate pharmacologic treatment trials.
FDA device clearance materials reinforce this positioning. Adult TMS systems are cleared for patients who haven’t achieved satisfactory improvement from prior antidepressant medication in the current episode. That language frames TMS as a next step, not a first move.
That said, the path to TMS isn’t always purely about medication failure. Some patients tolerate antidepressants poorly and can’t complete an adequate trial. Others simply prefer a non-systemic option that works on brain activity directly rather than through the bloodstream. Both scenarios can make TMS a reasonable consideration. The key is that the decision happens within a structured psychiatric treatment review, not in isolation.
Using TMS Alongside Other Depression Treatments
TMS is rarely a standalone treatment, and the clinical evidence supports that view clearly. A comparative study summarized by NEJM Clinician followed 89 patients who hadn’t responded to at least two antidepressants. Those who received 25 rTMS sessions over eight weeks (added on top of their current antidepressant, while both groups also participated in psychotherapy) showed meaningfully better outcomes than those who simply switched antidepressants: a 38% response rate versus 15%, and a remission rate of 27% versus 5%. TMS functioned as an augmentation strategy within a broader care package, not as a replacement for it.
TMS doesn’t cancel out therapy. It doesn’t necessarily mean stopping medication. Repetitive transcranial magnetic stimulation (rTMS) is an effective and safe treatment for major depressive disorder, and its positioning in modern care reflects that: a meaningful option between standard outpatient depression treatment and more intensive interventions like ECT.
One reason TMS integrates well with therapy is the neuroplasticity question. TMS uses magnetic pulses to stimulate underactive regions of the brain involved in mood regulation. That stimulation appears to create a window of increased neural flexibility. Psychotherapy, particularly CBT, can help direct that flexibility toward healthier patterns of thinking and behavior.
Medication sometimes continues during TMS, sometimes gets tapered depending on how the patient is responding. Lifestyle factors, like sleep, exercise, and stress management, stay relevant throughout. The treatment picture during a TMS course is usually still a full picture, with TMS added into it rather than replacing everything else.
How Clinicians Integrate TMS Into Ongoing Care
Integrating TMS into a treatment plan starts before the first session. Clinicians conduct an initial evaluation to confirm the patient is an appropriate candidate. They review diagnosis, treatment history, symptom severity, contraindications (like metal implants or seizure history), and what other parts of care are currently in place.
From there, a standard TMS course typically involves sessions five days a week for four to six weeks, with each session lasting anywhere from a few minutes to about 40 minutes, depending on the protocol. Accelerated protocols exist as well, compressing that timeline. Either way, the time commitment is real, and it affects how the broader treatment plan is managed. Clinicians still need to track symptoms week by week, coordinate with therapists, and stay responsive to how the patient is tolerating the process.
Response monitoring continues after the acute course ends. Some patients reach significant remission. Others see partial improvement that guides next steps. For those who respond well, maintenance becomes the next planning question.
The MAINT-R randomized trial looked at 75 adults with treatment-resistant depression who had already responded to an acute rTMS course. Maintenance rTMS and lithium showed comparable efficacy in preventing relapse over 24 weeks, with no significant difference in relapse rates, but the rTMS group had fewer adverse events (3 versus 16 in the lithium group). It’s a relatively small trial conducted in Japan, so the findings shouldn’t be applied universally, but it does support the idea that TMS can extend into the maintenance phase of care rather than ending at the acute course.
That’s important for understanding what “integrating TMS into ongoing care” looks like. For some patients, it means a defined six-week course followed by re-evaluation. For others, it may mean periodic maintenance sessions built into a longer-term psychiatric treatment plan.
The ketamine treatment options, also placed in the advanced-care portion of the VA/DoD treatment sequence, occupy similar territory, offering clinicians additional tools for patients who need more than standard outpatient care can provide. No two plans look identical, which is exactly why structured, individualized planning matters.
Your Treatment, Fully Orchestrated: Let Zeam Conduct the Plan
TMS therapy isn’t a standalone experiment or a last resort people stumble into. It’s a carefully positioned option within a structured depression treatment plan that works best when it’s integrated thoughtfully alongside medication management, psychotherapy, and active monitoring rather than dropped in on its own.
At Zeam, we build that structure around each patient. Our team in Sacramento, Folsom, and Roseville evaluates where someone is in their treatment journey, what’s worked, what hasn’t, and where TMS or our other advanced options like ketamine therapy genuinely belong in the picture. If you’re wondering whether TMS might be the right next step for you, we’d like to help you figure that out. Contact us today to schedule a consultation and see how TMS could fit into your care plan.
Key Takeaways
- Depression treatment follows a structured progression – Psychiatric care typically begins with medication and therapy, then advances to augmentation strategies and interventional treatments like TMS when needed.¹
- TMS is introduced after standard treatments fall short – Clinical guidelines recommend considering TMS for patients who have not responded adequately to two or more antidepressant trials.¹
- FDA positioning reinforces TMS as a next-step treatment – TMS devices are cleared for patients who have not achieved sufficient improvement from prior antidepressant use in the current episode.²
- TMS is usually part of a combined treatment approach – Research shows that TMS works best when used alongside psychotherapy and, in some cases, medication rather than as a standalone treatment.³
- Clinical evidence supports TMS as an augmentation strategy – Studies demonstrate higher response and remission rates when TMS is added to existing treatment compared to switching medications alone.³
- TMS supports neuroplasticity and therapy engagement – By stimulating underactive brain regions, TMS may create a window where psychotherapy becomes more effective in reshaping thought patterns.
- Treatment plans continue evolving during and after TMS – Clinicians monitor progress throughout the treatment course and adjust care based on response, tolerability, and functional improvement.
- Maintenance TMS may help sustain long-term outcomes – Research suggests maintenance TMS can reduce relapse risk and may offer fewer adverse effects compared to some pharmacologic strategies.⁴
Citations
- VA/DoD Clinical Practice Guideline for Major Depressive Disorder
https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/mdd/VADODMDDCPGFinal508.pdf - FDA Clearance Summary for TMS Devices
https://www.accessdata.fda.gov/cdrh_docs/pdf24/K243460.pdf - NEJM Clinician Summary on rTMS for Refractory Depression
https://clinician.nejm.org/repetitive-transcranial-magnetic-stimulation-refractory-depression-nejm-jw.NA58005 - MAINT-R Trial (JAMA Network Open)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835319
